Clinical grade production and characterization of a fusion protein comprised of the chemokine CCL2-ligand genetically fused to a mutated and truncated form of the Shiga A1 subunit

Protein Expression and Purification

Volumn 66, Issue 2, 2009, Pages 149-157

  Su, Hongsheng ^a   Jack, Michael ^a   McIntosh, Laura M ^a   Perdomo, Liliana ^a   Choy, Bonny S F ^a   Finck, Barbara K ^b   McDonald, John R ^a  

^a Osprey Pharmaceuticals Limited   (Canada)

^b Osprey Pharmaceuticals USA Inc   (United States)

Author keywords

CCL2; Chemokine; Fusion protein; GMP; Shiga A1 subunit

Indexed keywords

4 AMINOPYRAZOLO(3,4 D)PYRIMIDINE; 4-AMINOPYRAZOLO(3,4-D)PYRIMIDINE; ADENINE; DRUG DERIVATIVE; HYBRID PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN SYNTHESIS INHIBITOR; SHIGA TOXIN;

AMINO ACID SEQUENCE; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY; DRUG ANTAGONISM; DRUG EFFECT; ESCHERICHIA COLI; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; RIBOSOME;

ADENINE; AMINO ACID SEQUENCE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOKINE CCL2; CHROMATOGRAPHY; ESCHERICHIA COLI; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN SYNTHESIS INHIBITORS; RECOMBINANT FUSION PROTEINS; RIBOSOMES; SHIGA TOXIN;

ORYCTOLAGUS CUNICULUS;

EID: 67349260508     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2009.02.015     Document Type: Article

References (46)

1. Le Y., Zhou Y., Iribarren P., and Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell. Mol. Immunol. 1 (2004) 95-104
2. Puneet P., Moochhala S., and Bhatia M. Chemokines in acute respiratory distress syndrome. Am. J. Physiol. Lung Cell. Mol. Physiol. 288 (2005) L3-L15
3. Bacon K., Baggiolini M., Broxmeyer H., Horuk R., Lindley I., Mantovani A., Maysushima K., Murphy P., Nomiyama H., Oppenheim J., Rot A., Schall T., Tsang M., Thorpe R., Van Damme J., Wadhwa M., Yoshie O., Zlotnik A., and Zoon K. Chemokine/chemokine receptor nomenclature. J. Interferon Cytokine Res. 22 (2002) 1067-1068
4. Murphy P.M. International union of pharmacology. XXX: update on chemokine receptor nomenclature. Pharmacol. Rev. 54 (2002) 227-229
5. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim L.H.J.J., and Power C.A. International union of pharmacology. XXII: nomenclature for chemokine receptors. Pharmacol. Rev. 52 (2000) 145-176
6. Segerer S., and Schlondorff D. Role of chemokines for the localization of leukocyte subsets in the kidney. Semin. Nephrol. 27 (2007) 260-274
7. Thelen M., and Stein J.V. How chemokines invite leukocytes to dance. Nat. Immunol. 9 (2008) 953-959
8. Neel N.F., Schutyser E., Sai J., Fan G.H., and Richmond A. Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev. 16 (2005) 637-658
9. Proudfoot A.E. The biological relevance of chemokine-proteoglycan interactions. Biochem. Soc. Trans. 34 (2006) 422-426
10. Allen S.J., Crown S.E., and Handel T.M. Chemokine: receptor structure, interactions, and antagonism. Annu. Rev. Immunol. 25 (2007) 787-820
11. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
12. Rovin B.H. The chemokine network in systemic lupus erythematous nephritis. Front. Biosci. 13 (2008) 904-922
13. Ruster C., and Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front. Biosci. 13 (2008) 944-955
14. Wada T., Matsushima K., and Kaneko S. The role of chemokines in glomerulonephritis. Front. Biosci. 13 (2008) 3966-3974
15. McDonald J.R., McManaman J.L., and Yong V.W. The therapeutic potential of chemokine-toxin fusion proteins. IDrugs 4 (2001) 427-442
16. Kluth D.C., Erwig L.P., and Rees A.J. Multiple facets of macrophages in renal injury. Kidney Int. 66 (2004) 542-557
17. Sean Eardley K., and Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int. 68 (2005) 437-455
18. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 25 (2006) 357-371
19. Pollard J.W. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 84 (2008) 623-630
20. Kalinowska A., and Losy J. Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases. Expert Opin. Investig. Drugs 17 (2008) 1267-1279
21. Vital E.M., and Emery P. The development of targeted therapies in rheumatoid arthritis. J. Autoimmun. 31 (2008) 2993-2999
22. Folkerts G., Kraneveld A.D., and Nijkamp F.P. New endogenous CXC chemokine ligands as potential targets in lung emphysema. Trends Pharmacol. Sci. 29 (2008) 181-185
23. McIntosh L.M., Barnes J.L., Barnes V.L., and McDonald J.R. Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin. Exp. Immunol. 155 (2008) 295-303
24. Skinner L.M., and Jackson M.P. Investigation of ribosome binding by the Shiga toxin A1 subunit, using competition and site-directed mutagenesis. J. Bacteriol. 179 (1997) 1368-1374
25. Skinner L.M., and Jackson M.P. Inhibition of prokaryotic translation by the Shiga toxin enzymatic subunit. Microb. Pathog. 24 (1998) 117-122
26. Suh J.K., Hovde C.J., and Robertus J.D. Shiga toxin attacks bacterial ribosomes as effectively as eucaryotic ribosomes. Biochemistry 37 (1998) 9394-9398
27. Burgess R.R., and Jendrisak J.J. A procedure for the rapid, large-scale purification of Escherichia coli DNA-dependent RNA polymerase involving Polymin P precipitation and DNA-cellulose chromatography. Biochemistry 14 (1975) 4634-4638
28. Guerrier L., Girot P., Schwartz W., and Boschetti E. New method for the selective capture of antibodies under physiological conditions. Bioseparation 9 (2000) 211-221
29. i) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
30. Armes L.G., and Forney L.J. The complete primary structure of pilin from Haemophilus influenzae type b strain Eagan. J. Protein Chem. 9 (1990) 45-52
31. Reiner C.K., Kada G., and Gruber H.J. Quick measurement of protein sulfhydryls with Ellman's reagent and with 4,4′-dithiopyridine. Anal. Bioanal. Chem. 373 (2002) 266-276
32. Stirpe F. Ribosome-inactivating proteins. Toxicon 44 (2004) 371-383
33. Brigotti M., Carnicelli D., Accorsi P., Rizzi S., Montanaro L., and Sperti S. 4-Aminopyrazolo[3,4-d]pyrimidine (4-APP) as a novel inhibitor of the RNA and DNA depurination induced by Shiga toxin 1. Nucleic Acids Res. 28 (2000) 2383-2388
34. Brigotti M., Rizzi S., Carnicelli D., Montanaro L., and Sperti S. A survey of adenine and 4-aminopyrazolo[3,4-d]pyrimidine (4-APP) as inhibitors of ribosome-inactivating proteins (RIPs). Life Sci. 68 (2000) 331-336
35. Haddad J.E., al-Jaufy A.Y., and Jackson M.P. Minimum domain of the Shiga toxin A subunit required for enzymatic activity. J. Bacteriol. 175 (1993) 4970-4978
36. Yoshimura T., and Leonard E.J. Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes. J. Immunol. 145 (1990) 292-297
37. Charo I.F., Myers S.J., Herman S.A., Franci C., Connolly A.J., and Coughlin S.R. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA 91 (1994) 2752-2756
38. Kito K., Morishita K., and Nishida K. MCP-1 receptor binding affinity is up-regulated by pre-stimulation with MCP-1 in an actin polymerization-dependent manner. J. Leukoc. Biol. 69 (2001) 666-674
39. Clark-Lewis I., Kim K.S., Rajarathnam K., Gong J.H., Dewald B., Moser B., Baggiolini M., and Sykes B.D. Structure-activity relationships of chemokines. J. Leukoc. Biol. 57 (1995) 703-711
40. Hemmerich S., Paavola C., Bloom A., Bhakta S., Freedman R., Grunberger D., Krstenansky J., Lee S., McCarley D., Mulkins M., Wong B., Pease J., Mizoue L., Mirzadegan T., Polsky I., Thompson K., Handel T.M., and Jarnagin K. Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. Biochemistry 38 (1999) 13013-13025
41. Kreitman R.J., Puri R.K., and Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res. 55 (1995) 3357-3363
42. Kreitman R.J. Toxin-labeled monoclonal antibodies. Curr. Pharm. Biotechnol. 2 (2001) 313-325
43. Golay J., Di Gaetano N., Amico D., Cittera E., Barbui A.M., Giavazzi R., Biondi A., Rambaldi A., and Introna M. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br. J. Haematol. 128 (2005) 310-317
44. Baatar D., Olkhanud P., Newton D., Sumitomo K., and Biragyn A. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J. Immunol. 179 (2007) 1996-2004
45. Lu Y., Cai Z., Galson D.L., Xiao G., Liu Y., George D.E., Melhem M.F., Yao Z., and Zhang J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66 (2006) 1311-1318
46. Agrawal S., Johnson T., Silva C., McDonald J., McIntosh L., Coggins P., and Yong P.V.W. Evaluation of a leukocyte population modulator (LPM), OPL-CCL2-LPM, in experimental autoimmune encephalomyelitis (EAE). Neurology 70 Suppl. 1 (2008) A411